Shoulder Innovations, Inc.
NYSE:SIMedical - Specialties
-$0.13 today
- Market cap
- $432.04M
- Beta
- -1.07
- P/E (TTM)
- -8.4
- EPS (TTM)
- -$2.13
Volume 0.09M
Average 0.10M
SI Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Shoulder Innovations, Inc.NYSE: SI
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -50.1%
Net margin was -50.1% in Q1 FY2026, down 4.1 pp from a year earlier. On a trailing-twelve-month basis it was -81.8%, down 33.5 pp year over year.
Context
- Net margin widened in 1 of the last 2 fiscal years.
- FY2025 was the lowest level in the 3 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 3 analysts of -50.3% for the fiscal year ending Dec 2026, up from -85.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -50.1%+3.8 pp QoQ
- Last fiscal yearDec 2025
- -85.3%-35.9 pp YoY
- LTMMar 2026
- -81.8%-33.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.1 pp | +116.6 pp | +120.7 pp |
| 1 year | -35.9 pp | +35.0 pp | +70.9 pp |
| 3 years | — | +56.0 pp | — |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -85.3%
- Year-over-year change
- -35.9pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -85.3% | -35.9pp |
| FY2024 | 2024-12-31 | -49.4% | +16.3pp |
| FY2023 | 2023-12-31 | -65.7% | — |
Net Margin vs competitors
How SI compares with its peers on the latest reported figures
- SI's LTM Mar 2026 net margin of -81.8% is the 6th highest of the 8 companies compared; the peer median is -31.1%.
- Its year-over-year change of -33.5 pp is the 7th highest of 8, against a peer median of +35.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 36.2% | +126.1 pp | +88.3 pp | |
| LTM Mar 2026 | -7.1% | +1.0 pp | +15.7 pp | |
| LTM Mar 2026 | -9.0% | +115.2 pp | — | |
| FY2025 | -31.1% | +11.2 pp | +87.8 pp | |
| LTM Mar 2026 | -63.7% | +35.1 pp | +72.9 pp | |
| LTM Mar 2026 | -81.8% | -33.5 pp | — | |
| LTM Mar 2026 | -89.6% | +60.0 pp | +16.0 pp | |
| LTM Dec 2025 | -576.1% | -101.8 pp | +650.8 pp | |
EPRXEupraxia Pharmaceuticals Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding SI) | -31.1% | +35.1 pp | +80.3 pp | |
Competitors are the stored peer set for SI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 19.27M | 31.62M | 47.32M |
| Cost of Revenue | 4M | 7.28M | 11.12M |
| Gross Profit | 15.27M | 24.34M | 36.2M |
| Gross Margin | 79.2% | 77.0% | 76.5% |
| Research & Development | 3.02M | 4.49M | 7.73M |
| Selling, General & Admin | 23.11M | 34.51M | 54.77M |
| Operating Expenses | 26.13M | 38.99M | 62.5M |
| Depreciation & Amortization | 1.64M | 2.2M | 3.21M |
| EBITDA | (10.25M) | (12.11M) | (37.08M) |
| EBITDA Margin | -53.2% | -38.3% | -78.4% |
| Operating Income | (10.86M) | (14.65M) | (26.3M) |
| Operating Margin | -56.4% | -46.3% | -55.6% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 761K | 1.32M | 70K |
| Other Income / Expenses | (1.79M) | (966K) | (14.06M) |
| Income Before Tax | (12.66M) | (15.62M) | (40.36M) |
| Pre-Tax Margin | -65.7% | -49.4% | -85.3% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (12.66M) | (15.62M) | (40.36M) |
| Net Margin | -65.7% | -49.4% | -85.3% |
| EPS (Basic) | (0.63) | (0.77) | (1.96) |
| EPS (Diluted) | (0.63) | (0.77) | (1.96) |
| Weighted Avg Shares | 19.92M | 19.92M | 20.63M |
| Weighted Avg Shares (Diluted) | 19.92M | 19.92M | 20.63M |
Shoulder Innovations, Inc.
NYSE:SI
Intrinsic Alpha fair value
Locked
Current Price
$20.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.